Settings
ESRX [NASD]
Express Scripts Holding Company
IndexS&P 500 P/E33.63 EPS (ttm)2.52 Insider Own0.23% Shs Outstand733.91M Perf Week-0.74%
Market Cap62.20B Forward P/E15.55 EPS next Y5.45 Insider Trans-9.16% Shs Float732.23M Perf Month-1.32%
Income1.94B PEG2.53 EPS next Q1.38 Inst Own86.60% Short Float2.43% Perf Quarter16.00%
Sales100.36B P/S0.62 EPS this Y28.30% Inst Trans-0.11% Short Ratio4.60 Perf Half Y27.73%
Book/sh27.31 P/B3.10 EPS next Y11.70% ROA3.60% Target Price88.80 Perf Year15.59%
Cash/sh1.14 P/C74.51 EPS next 5Y13.29% ROE9.10% 52W Range64.64 - 86.64 Perf YTD0.09%
Dividend- P/FCF15.27 EPS past 5Y8.40% ROI6.80% 52W High-2.95% Beta1.19
Dividend %- Quick Ratio0.50 Sales past 5Y36.50% Gross Margin7.90% 52W Low30.07% ATR1.65
Employees29975 Current Ratio0.60 Sales Q/Q-0.50% Oper. Margin3.50% RSI (14)50.72 Volatility1.84% 1.81%
OptionableYes Debt/Eq0.73 EPS Q/Q44.40% Profit Margin1.90% Rel Volume0.62 Prev Close84.75
ShortableYes LT Debt/Eq0.57 EarningsFeb 23 AMC Payout0.00% Avg Volume3.86M Price84.08
Recom2.10 SMA20-0.63% SMA501.26% SMA20013.43% Volume1,543,244 Change-0.79%
Jan-08-15Reiterated Mizuho Buy $82 → $94
Dec-16-14Reiterated Oppenheimer Outperform $82 → $88
Dec-15-14Reiterated UBS Buy $82 → $96
Dec-04-14Reiterated Deutsche Bank Hold $76 → $88
Dec-03-14Reiterated Barclays Overweight $83 → $94
Oct-30-14Reiterated RBC Capital Mkts Outperform $73 → $82
Jul-30-14Reiterated FBR Capital Outperform $79 → $74
Jul-28-14Reiterated UBS Buy $90 → $82
May-01-14Reiterated Maxim Group Buy $92 → $90
Apr-30-14Reiterated Mizuho Buy $86 → $82
Mar-06-14Reiterated Deutsche Bank Hold $75 → $79
Mar-05-14Reiterated RBC Capital Mkts Outperform $72 → $84
Mar-05-14Initiated Barclays Overweight $85
Feb-21-14Reiterated FBR Capital Outperform $75 → $83
Feb-19-14Reiterated Maxim Group Buy $80 → $92
Feb-18-14Downgrade Monness Crespi & Hardt Buy → Neutral
Jan-17-14Reiterated Mizuho Buy $74 → $86
Nov-21-13Initiated Deutsche Bank Hold $73
Oct-24-13Initiated FBR Capital Outperform $75
Jul-31-13Reiterated Oppenheimer Outperform $65 → $74
Jan-26-15 12:00AM  Want To Control Drug Prices? Reject Price Controls at Forbes
Jan-24-15 11:58AM  German insurers win discounts on Gilead's Sovaldi Reuters
Jan-22-15 07:49PM  The Drug Price War Pitting Insurers Against Big Pharma at Bloomberg
02:42PM  Express Scripts Targets $150,000 Cancer Drug Prices in 2016 Plan at Bloomberg
Jan-21-15 02:13PM  Gilead, AbbVie Hep C Price Cuts Seen Hitting Sales at Investor's Business Daily
Jan-20-15 10:00AM  Benefits firms shouldn't play drug favorites: CEO at CNBC
07:41AM  Regeneron CEO: Choice, not price best for patients CNBC
Jan-19-15 06:35PM  AbbVie Gains EU Approval for Hepatitis C Virus Treatment - Analyst Blog Zacks
Jan-18-15 10:32AM  5 Trade Ideas for Tuesday: Allstate, Anheuser-Busch InBev, Ashland, Express Scripts, Northrup Grumman, Yahoo Finance Contributors
Jan-16-15 05:34PM  Aetna picks Gilead Sciences hepatitis C drugs over AbbVie's AP
05:19PM  CORRECTED (OFFICIAL)-UPDATE 1-Aetna backs Gilead's hepatitis C treatment, gets discount Reuters
04:15PM  Express Scripts Announces Fourth Quarter 2014 Earnings Conference Call and Webcast of Investor Day Meeting PR Newswire
03:43PM  Aetna Sides With Gilead In Hepatitis C Drug Battle at Investor's Business Daily
03:08PM  Gilead Strikes Another Deal at Barrons.com
07:00AM  Express Scripts Holding Company (ESRX): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report Zacks
Jan-15-15 10:59AM  5 Breakout Trades for 2015 Gains: Apple, Goldman Sachs and More at TheStreet
01:00AM  Big Pharma faces up to new price pressure from aggressive insurers Reuters
Jan-14-15 04:02PM  Express Scripts facing antitrust, contract complaint at American City Business Journals
09:01AM  Cramer: Market in weird place CNBC
Jan-13-15 07:10PM  Steven Romick Buys 7 US and International Stocks in Q4 Gurufocus
06:14PM  Cramer's guide to a treacherous trader's market at CNBC
04:28PM  Express Scripts sees opportunity to lower cancer treatment cost Reuters
03:38PM  Express Scripts sees opportunity to lower cancer treatment costs Reuters
02:41PM  Will Earnings or the European Central Bank Prompt U.S. Stocks to Rise? at TheStreet
01:35PM  State of St. Louis: Stenger focuses on Childrens Service Fund at American City Business Journals
12:46PM  Express Scripts CEO: Amgen, Regeneron Among Targets for Drug Discounting at TheStreet
Jan-12-15 12:57PM  AmerisourceBergen Corporation -- Moody's affirms AmerisourceBergen's Baa2 rating on news of MWI Veterinary acquisition at Moody's
11:03AM  Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 2 Benzinga
Jan-09-15 11:49AM  AbbVie Stock Down After Guidance, Downgrade at Investor's Business Daily
09:55AM  Gilead Sciences: Winning at Barrons.com
09:22AM  The Express Scripts-AbbVie Deal Raises Concern Over Patient Choices at The Wall Street Journal
06:30AM  Citizens Bank sells former regional HQ in Albany at bizjournals.com
Jan-08-15 05:03PM  Anthem selects Gilead as primary supplier of hepatitis C drugs Reuters
04:15PM  FDA panel OKs copy of Amgens Neupogen cancer drug at bizjournals.com
01:09PM  Biotech Investors Guide and Preview to the J.P. Morgan Healthcare Conference Part 1 at TheStreet
09:10AM  Hepatitis C Drug Discount Deals Still Miss Many Patients at Forbes
07:26AM  What A Drug Price Debate Reveals About Obamacare at Forbes
Jan-06-15 07:03PM  Express Scripts to Present at the J.P. Morgan Healthcare Conference PR Newswire
11:04AM  Cramer: Gilead 'Back in the Driver's Seat' After CVS Deal at TheStreet
06:37AM  Pharma pricing wars... who wins? CNBC
Jan-05-15 06:09PM  Gilead hepatitis-C drug wins CVS/Caremark backing at Financial Times
04:03PM  EXPRESS SCRIPTS HOLDING CO. Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
03:09PM  CVS Picks Gilead Hep C Drugs As Price War Looms at Investor's Business Daily
02:35PM  Pharmacy giant CVS opts to exclusively offer Gilead's pricey hepatitis C drug at bizjournals.com
02:22PM  Gilead Sciences: Take That AbbVie! at Barrons.com
01:05PM  Gilead fights back: CVS deal sends shares soaring at CNBC
10:41AM  Drug pricing concerns? Not at Gilead at CNBC
09:43AM  2015 Biotech Sector Outlook: Bullish but be Wary About Drug Pricing Yahoo Finance Blogs
07:00AM  Verizon and Gilead Sciences skew 4Q earnings growth Yahoo Finance
Jan-02-15 09:36AM  Express Scripts Stock Dominated Q4; Which Funds Might've Won? Benzinga
Jan-01-15 04:46AM  Pharma and biotech on a roll as drug approvals hit 18-year high Reuters
Dec-31-14 07:20AM  Jobs come and go at Tampa Bay workplaces in 2014 at bizjournals.com
Dec-30-14 07:00AM  The Most Important New Drug Of 2014 at Forbes
Dec-29-14 05:18PM  Right time for Gilead buyback: Pro CNBC
11:59AM  Stocks Hold Near Highs; LifeLock Breaks Out at Investor's Business Daily
11:06AM  Is It Time to Buy Gilead? Morgan Stanley Thinks So at Barrons.com
07:18AM  Bullish on biotech CNBC
Dec-27-14 08:02AM  Facebook Among IBD 50's Top 5 Earnings Kings In 2014 at Investor's Business Daily
12:01AM  Barron's 10 Favorite Stocks for 2015 at Barrons.com
Dec-26-14 06:27PM  IBD 50: Biotechs Hammered, Then Find Support at Investor's Business Daily
02:34PM  Street Talk: AKAM, GILD, GRPN, GPRO CNBC
Dec-24-14 06:24PM  Biotech Stocks Take A Beating, But Find Support at Investor's Business Daily
03:25PM  Celgene Wins, GameStop Loses in Abbreviated Trading at Barrons.com
11:57AM  Stocks Score Small Gains; Virgin America Takes Flight at Investor's Business Daily
10:42AM  Mini rebound in biotechs CNBC
09:01AM  Cramer: Profit taking essential CNBC
08:23AM  Morning Movers: Cal-Maine Dissapoints; Can Gilead Stabilize? at Barrons.com
07:14AM  Bulls flying with Express Scripts optionMONSTER
05:30AM  Express Scripts Sees Heavy Call Volume as Bulls Clean Up at TheStreet
Dec-23-14 08:05PM  Biogen Straps Fitbits Onto MS Patients' Wrists at BusinessWeek
06:15PM  Off the Charts: Biotech breakdown CNBC
04:24PM  US STOCKS-Dow ends above 18k for first time on strong GDP report Reuters
04:20PM  Tracking biotech pullback CNBC
04:13PM  Evercore ISI Analyst: 160,000 Patients Affected by AbbVie Hepatitis Pact Benzinga
04:11PM  Dow tops 18,000 as market reaches new highs AP
03:00PM  Hepatitis C drug wars CNBC
01:18PM  US STOCKS-GDP lifts Dow over 18k; biotechs have worst day since April Reuters
01:17PM  Chesapeake buyback cheers investors at Financial Times
01:07PM  Pisani: Stocks that moved Dow from 17K-18K CNBC
01:00PM  HALFTIME REPORT FINAL TRADES at CNBC
12:58PM  FMHR Final Trade: ALSN, BP, SCHW & ESRX CNBC
12:15PM  Analysts Predict Big Value Trap for Gilead Investors at 24/7 Wall St.
11:01AM  Gilead Sciences Is Not a Buy; It's Heading Lower on Price War: Jim Cramer at TheStreet
09:24AM  Cramer's Mad Dash: Wait on Gilead CNBC
08:15AM  US STOCKS-Futures edge up after latest record; data on tap Reuters
05:00AM  'Fast Money' Recap: The World's Investment Money Is Coming to the U.S. at TheStreet
Dec-22-14 06:23PM  Actavis, Valeant Largely Avoid Gilead's Hepatitis Dive at Investor's Business Daily
05:15PM  Hep C drug wars: GILD a buy? CNBC
04:48PM  US STOCKS-Dow, S&P end at records in 4th straight day of gains for Wall St Reuters
04:44PM  Express Scripts turns to AbbVie in huge hepatitis C deal AP
04:20PM  US STOCKS-Wall St up for fourth straight day; S&P ends at record Reuters
03:53PM  Gilead's Stock Drop Smacks Health-Care Funds at Barrons.com
03:17PM  US stock indexes drift higher in afternoon trading AP
02:50PM  US STOCKS-Wall St on track for four-day rally; tech lifts Dow Reuters
02:12PM  Express Scripts drops Gilead hep C drugs for cheaper AbbVie rival Reuters
01:58PM  Inside AbbVie's exclusive deal CNBC
01:35PM  Gilead slides after hepatitis drug setback at Financial Times
01:09PM  US STOCKS-Wall St edges up after three-day run; tech lifts Dow Reuters
12:34PM  Drug Price War Takes Pharma Back To The Future at Forbes
12:27PM  4 Stocks, 4 trades: Gilead, Russia & more CNBC
Express Scripts Holding Company provides a range of pharmacy benefit management (PBM) services primarily in the United States and Canada. The company offers healthcare management and administration services on behalf of its clients. It operates in two segments, PBM and Other Business Operations. The company's PBM services comprise retail network pharmacy administration; home delivery pharmacy; benefit design consultation; drug utilization review; drug formulary management; clinical solutions to improve health outcomes; an array of Medicare Part D, Medicaid, and health insurance marketplace; specialty pharmacy services, such as the distribution of fertility pharmaceuticals that require special handling or packaging; bio- pharmaceutical services, including reimbursement and logistics solutions; group purchasing organization administration; and consumer health and drug information services. It is also involved in the distribution of pharmaceuticals and medical supplies to providers and clinics; development of scientific evidence to guide the use of medicines; and provision of case management approach to manage care by integrating pre-certification, case management, and discharge planning services for patients. Express Scripts Holding Company provides its PBM services to managed care organizations, health insurers, third-party administrators, employers, union-sponsored benefit plans, workers' compensation plans, and government health programs; and specialty services to managed care organizations, health insurers, third-party administrators, employers, union-sponsored benefit plans, government health programs, office-based oncologists, renal dialysis clinics, ambulatory surgery centers, primary care physicians, retina specialists, and others. The company was formerly known as Aristotle Holding, Inc. and changed its name to Express Scripts Holding Company in April 2012. Express Scripts Holding Company was founded in 1986 and is headquartered in St. Louis, Missouri.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ebling Keith J.Exec. VP and General CounselDec 02Sale84.2510,000842,5000Dec 03 04:04 PM
Miller Steven BSr. VP & Chief Med. OfficerDec 01Sale83.574,896409,14416,521Dec 03 04:07 PM
Stettin Glen D.Sr. VP, Clin. Res. & New Sol.Nov 28Option Exercise47.6110,800514,18830,657Dec 01 04:03 PM
Stettin Glen D.Sr. VP, Clin. Res. & New Sol.Nov 28Sale82.9610,800895,94619,857Dec 01 04:03 PM
Stettin Glen D.Sr. VP, Clin. Res. & New Sol.Nov 21Option Exercise47.6110,874517,71130,731Nov 25 04:38 PM
MAC MAHON THOMAS PDirectorNov 21Option Exercise35.8512,694455,01654,066Nov 25 04:40 PM
MAC MAHON THOMAS PDirectorNov 21Sale80.9312,6941,027,35141,372Nov 25 04:40 PM
Stettin Glen D.Sr. VP, Clin. Res. & New Sol.Nov 21Sale81.5010,874886,23119,857Nov 25 04:38 PM
PARKER JOHN ODirectorNov 17Option Exercise33.3025,822859,75365,503Nov 18 05:04 PM
PARKER JOHN ODirectorNov 17Sale78.7525,8222,033,43139,681Nov 18 05:04 PM
Breen Maura CDirectorNov 07Option Exercise30.8313,128404,73630,438Nov 10 04:16 PM
Breen Maura CDirectorNov 07Sale77.8013,1281,021,34517,310Nov 10 04:16 PM
IGNACZAK EDWARD BEVPSep 05Sale75.289,886744,21675,996Sep 09 05:01 PM
STERNBERG SEYMOURDirectorAug 28Option Exercise54.3015,508842,07920,277Sep 02 04:07 PM
STERNBERG SEYMOURDirectorAug 28Sale74.1215,5081,149,3914,769Sep 02 04:07 PM
Ebling Keith J.Exec. VP and General CounselAug 25Sale75.5010,000755,00010,000Aug 26 04:04 PM
Wade Sara ESr. VP, Ch. Human Res. Off.Aug 05Option Exercise53.0520,0001,061,00049,532Aug 06 04:10 PM
BENANAV GARY GDirectorAug 05Option Exercise35.8512,694455,01655,705Aug 07 04:08 PM
BENANAV GARY GDirectorAug 05Sale70.8212,694898,98943,011Aug 07 04:08 PM
Wade Sara ESr. VP, Ch. Human Res. Off.Aug 05Sale70.4420,0001,408,80029,532Aug 06 04:10 PM
Norton David ASenior VP, Supply ChainAug 04Sale71.021,27690,6270Aug 06 04:13 PM
Breen Maura CDirectorAug 01Option Exercise35.8512,694455,01630,283Aug 05 04:55 PM
Breen Maura CDirectorAug 01Sale69.9412,694887,75517,589Aug 05 04:55 PM
PAZ GEORGEChairman & CEOJun 13Option Exercise26.68681,50818,179,3841,469,761Jun 17 05:04 PM
PAZ GEORGEChairman & CEOJun 13Sale71.21681,50848,530,185788,253Jun 17 05:04 PM
WENTWORTH TIMOTHY CPresidentMay 27Option Exercise47.25127,1896,009,516228,492May 29 05:03 PM
WENTWORTH TIMOTHY CPresidentMay 27Sale70.47105,6777,447,058122,815May 29 05:03 PM
Wimberly GarySr. VP & Ch. Information Off.Mar 13Option Exercise45.3934,5361,567,69758,157Mar 17 04:34 PM
Wimberly GarySr. VP & Ch. Information Off.Mar 13Sale78.4144,4973,489,09913,660Mar 17 04:34 PM
Houston ChristineSr. Vice President, OperationsMar 12Option Exercise31.9215,674500,31438,071Mar 14 06:24 PM
Houston ChristineSr. Vice President, OperationsMar 12Sale78.5319,7571,551,45818,314Mar 14 06:24 PM
IGNACZAK EDWARD BExec. VP, Sales and MktgMar 11Option Exercise55.14120,2476,630,559206,129Mar 13 05:42 PM
IGNACZAK EDWARD BExec. VP, Sales and MktgMar 11Sale78.54120,2479,443,83985,882Mar 13 05:42 PM
Norton David ASenior VP, Supply ChainMar 11Sale79.153,160250,123630Mar 13 05:38 PM
Ebling Keith J.Exec. VP and Gen. CounselMar 11Sale79.009,582756,97820,000Mar 11 06:02 PM
Miller Steven BSr. VP & Chief Med. OfficerMar 10Sale77.9612,664987,29821,417Mar 12 06:05 PM
McNamee PatrickExec. VP and COOMar 10Sale78.2227,9812,188,5627,664Mar 12 06:03 PM
McNamee PatrickExec. VP and COOMar 10Sale78.3240,4443,167,69512,421Mar 12 06:03 PM
Stettin Glen D.Sr. VP, Clin. Res. & New Sol.Mar 07Option Exercise47.1437,4311,764,58363,624Mar 11 06:04 PM
Ebling Keith J.Exec. VP and Gen. CounselMar 07Option Exercise49.509,901490,05038,361Mar 11 06:02 PM
Ebling Keith J.Exec. VP and Gen. CounselMar 07Sale78.5016,1391,266,92822,222Mar 11 06:02 PM
Stettin Glen D.Sr. VP, Clin. Res. & New Sol.Mar 07Sale78.2243,7673,423,23919,857Mar 11 06:04 PM
Ebling Keith J.Exec. VP and Gen. CounselMar 07Sale77.6737,6612,925,17829,582Mar 07 06:44 PM
Ebling Keith J.Exec. VP and Gen. CounselMar 06Option Exercise49.5036,8091,821,86165,269Mar 07 06:44 PM
Ebling Keith J.Exec. VP and Gen. CounselMar 06Sale78.5036,8092,889,54328,460Mar 07 06:44 PM
STERNBERG SEYMOURDirectorMar 05Option Exercise30.8313,128404,73616,406Mar 07 06:56 PM
Ebling Keith J.Exec. VP and Gen. CounselMar 05Option Exercise23.81139,8623,329,652198,241Mar 07 06:44 PM
STERNBERG SEYMOURDirectorMar 05Sale76.5013,1281,004,3053,278Mar 07 06:56 PM
Ebling Keith J.Exec. VP and Gen. CounselMar 05Sale77.0051,1163,935,9320Mar 07 06:44 PM
Ebling Keith J.Exec. VP and Gen. CounselMar 05Sale77.03169,78113,078,06128,460Mar 07 06:44 PM
ROPER WILLIAM LDirectorFeb 25Option Exercise39.0341,4961,619,56051,894Feb 27 05:14 PM
ROPER WILLIAM LDirectorFeb 25Sale74.0841,4963,073,81610,398Feb 27 05:14 PM
Houston ChristineSr. Vice President, OperationsFeb 21Option Exercise19.668,948175,93621,177Feb 25 04:46 PM